Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Pepa, Chiara, Banerjee, Susana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069138/
https://www.ncbi.nlm.nih.gov/pubmed/24971016
http://dx.doi.org/10.2147/OTT.S40527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069138/
https://www.ncbi.nlm.nih.gov/pubmed/24971016
http://dx.doi.org/10.2147/OTT.S40527

Ejemplares similares